Cyteir Therapeutics, Inc. announced that as contemplated by the Plan of Complete Liquidation and Dissolution previously approved by the Company?s board of directors on September 7, 2023 and the Company?s stockholders on November 16, 2023, the company filed a certificate of dissolution (the ?Certificate of Dissolution?) with the Secretary of State of the State of Delaware on March 20, 2024. The Certificate of Dissolution, which became effective upon filing, provides for the dissolution of the Company under the General Corporation Law of the State of Delaware (the ?Dissolution?). For additional information regarding the Plan of Dissolution and the Dissolution.

In connection with the effectiveness of the Certificate of Dissolution, the Board fixed March 20, 2024 as the record date for determining stockholders entitled to receive any future distributions of available assets (the ?Common Stock Liquidation Distributions?). Accordingly, the Company instructed its transfer agent to close its stock transfer books and discontinue recording transfers of the Company?s common stock, $0.001 par value per share (the ?Common Stock?), effective as of the close of business on March 20, 2024 and to notify DTC of the same. As a result, the Common Stock will no longer be assignable or transferable on the Company?s books, other than transfers by will, intestate succession or operation of law.

The Company currently estimates that the aggregate amount of cash that will be available for the Common Stock Liquidation Distributions will be in the range of between $3.10 and $3.16 per share of Common Stock. These amounts may be paid in one or more distributions. The Company currently estimates that it will make its first distribution during the second quarter of 2024.